Limosilactobacillus Reuteri Atcc Pta 5289
Also known as: Lactobacillus reuteri, Probiotic strain, Limosilactobacillus reuteri, Limosilactobacillus reuteri ATCC PTA 5289
Overview
Limosilactobacillus reuteri ATCC PTA 5289 is a well-studied probiotic bacterium naturally occurring in the human gastrointestinal tract and other locales. It is frequently utilized as a dietary supplement aimed at enhancing gastrointestinal health, bolstering immune function, and potentially alleviating symptoms associated with respiratory infections. One of its notable characteristics is the production of reuterin, an antimicrobial compound possessing protective benefits. The existing body of research encompasses numerous clinical trials and evaluations, affirming the strain's safety and effects. While evidence is largely drawn from randomized controlled trials (RCTs) and systematic reviews, further meta-analyses could strengthen the overall conclusions about its efficacy.
Benefits
Limosilactobacillus reuteri has demonstrated several evidence-based benefits. Among these, it is particularly noted for its positive impact on respiratory health, where studies indicate a significant reduction in symptoms of pharyngitis and tonsillitis among children, including diminished fever and throat soreness. Furthermore, it may enhance oral health by lowering *Streptococcus mutans* levels, although this benefit varies in statistical significance across studies. Recent research outlined potential anti-inflammatory properties and increases in immune markers, making the strain particularly relevant for children suffering from respiratory conditions. Many studies indicate substantial reductions in symptom severity and duration following supplementation, generally becoming apparent within a few days.
How it works
Limosilactobacillus reuteri exerts its effects through modulation of the immune system and the production of antimicrobial substances like reuterin. The strain primarily interacts with the gastrointestinal and immune systems, potentially influencing inflammatory pathways and enhancing immune responses. While specific molecular targets remain unidentified, the bacterium is known to affect cytokine levels and immune cell functionality, promoting health and helping to mitigate infections.
Side effects
The safety profile of Limosilactobacillus reuteri ATCC PTA 5289 is sound, with an overall low incidence of adverse events reported that are comparable to placebo groups. Common side effects are minimal and not typically reported, while occasional mild gastrointestinal symptoms may arise (1-5%), although evidence for these is inconsistent. Rare side effects (less than 1%) have not been documented. There appear to be no significant drug interactions; however, caution is advised when taken alongside immunosuppressive medications. There are no major contraindications, yet individuals with severe immune deficiencies should consult healthcare professionals prior to starting supplementation. The strain is considered safe for children and adolescents, though pregnant or breastfeeding women should seek medical advice.
Dosage
Dosage recommendations for Limosilactobacillus reuteri ATCC PTA 5289 are not universally defined but often involve formulations with billions of CFU. The minimum effective dose has not been clearly established, but optimal dosages generally involve daily intake of sufficient CFUs to be effective. While maximum safe limits haven't been firmly established, higher doses are usually well-tolerated. Timing is flexible; supplementation can occur at any point during the day, preferably alongside food for optimal absorption. Various forms, including drops and tablets, are available, and the strain's ability to survive gastric transit supports effective colonization in the gastrointestinal tract.
FAQs
How should Limosilactobacillus reuteri be stored?
It should be stored in a cool, dry place to maintain its viability as a probiotic.
Is it safe for those with weakened immune systems?
Generally safe, but individuals who are immunocompromised should consult their healthcare provider.
What is the best time to take it?
It can be taken daily at any time, preferably with meals for better absorption.
What results can I expect from taking this probiotic?
Users may experience reduced symptoms of respiratory infections and improvements in oral health over time.
Can it cure infections?
No, Limosilactobacillus reuteri is not a cure but may help support the recovery process.
Research Sources
- https://pubmed.ncbi.nlm.nih.gov/33789556/ – This randomized controlled trial focused on children aged 6 months to 5 years, demonstrating that supplementation with Limosilactobacillus reuteri significantly alleviated symptoms of pharyngitis and tonsillitis, with notable improvements in days with runny nose and fever.
- https://pubmed.ncbi.nlm.nih.gov/34325540/ – Another RCT evaluated adolescents, revealing that those receiving Limosilactobacillus reuteri showed decreased levels of *Streptococcus mutans*, indicating potential oral health benefits. However, the small sample size limited strength of evidence.
- https://brill.com/view/journals/bm/12/2/article-p137_3.xml – A review of various Limosilactobacillus reuteri strains highlighted their anti-inflammatory effects and established their safety for consumption, providing necessary context for understanding the strain's health impacts.
- https://academic.oup.com/jimb/article/50/1/kuad041/7424978?login=false – This literature review indicated a broader understanding of Limosilactobacillus reuteri strains, including ATCC PTA 5289, emphasizing their safety profile and potential health benefits based on existing research.